Price: $7.1300
$0.24
3.483%
|
Day's High:
| $7.2065
| Week Perf:
| -2.6 %
|
Day's Low: |
$ 7.06 |
30 Day Perf: |
-3.26 % |
Volume (M): |
53 |
52 Wk High: |
$ 13.49 |
Volume (M$): |
$ 376 |
52 Wk Avg: |
$10.12 |
Open: |
$7.20 |
52 Wk Low: |
$6.83 |
|
|
Market Capitalization (Millions $) |
1,260 |
Shares
Outstanding (Millions) |
177 |
Employees |
3,072 |
Revenues (TTM) (Millions $) |
842 |
Net Income (TTM) (Millions $) |
-197 |
Cash Flow (TTM) (Millions $) |
783 |
Capital Exp. (TTM) (Millions $) |
203 |
Evotec Se
Evotec SE is a publicly-traded German biotechnology firm operating in the pharmaceutical and drug discovery industry. The company is headquartered in Hamburg, Germany, and has various locations and offices worldwide.
Evotec SE is primarily engaged in the development and discovery of drugs, which includes providing comprehensive solutions for the pharmaceutical industry. The company works with leading biopharmaceutical companies, academic institutions, and disease foundations, focusing on providing innovative solutions through collaborations and partnerships.
Founded in 1993, the company has over the years been focused on research and development, cutting-edge technologies and collaboration, drug discovery, and strategic partnerships. The company has built a reputation as a leading provider of high-value drug discovery services, particularly in the fields of neuroscience, oncology, and autoimmune diseases.
Their technology platform, called the "Evotec Operating System," integrates different lab technologies and data management capabilities, enabling high-throughput screening and drug identification. This platform has been instrumental in the company's success as it enables them to work collaboratively and efficiently in the drug discovery process.
Evotec SE's services range from target identification, validation, and optimization to drug screening, hit identification, and preclinical development. The company also offers customized solutions tailored for specific client needs and has several programs in clinical and pre-clinical stages of development.
Additionally, Evotec SE has an extensive drug development pipeline, which includes both proprietary programs as well as partnered programs. To date, the company has over 100 partners across the globe and an impressive portfolio of drug candidates.
In terms of financials, Evotec SE has been consistent in its revenue growth, with a revenue increase of 17% in 2020 compared to the previous year. As of mid-2021, the company reported a total of over 4,000 employees worldwide, showing significant growth and expansion over the years.
Overall, Evotec SE has established itself as a leading biotech company that leverages cutting-edge technologies, strategic partnerships, and collaboration in drug discovery and development. With a proven track record, a robust pipeline, and consistent growth, the company is well-positioned to continue making significant strides in the biotech industry.
Company Address: Essener Bogen 7 Hamburg 22419
Company Phone Number: 40 560810 Stock Exchange / Ticker: NASDAQ EVO
EVO is expected to report next financial results on May 11, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Neurogene Inc
Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment. Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.
|
Eyenovia Inc
Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future. 1. Co-Promotion Agreement with NovaBay Pharmaceuticals: Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.
|
Avenue Therapeutics Inc
Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition. Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Per Share |
Current |
Earnings (TTM) |
-1.11 $ |
Revenues (TTM) |
4.76 $
|
Cash Flow (TTM) |
4.43 $ |
Cash |
2.98 $
|
Book Value |
7.53 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-1.11 $
|
Revenues (TTM) |
4.76 $ |
Cash Flow (TTM) |
4.43 $ |
Cash |
2.98 $
|
Book Value |
7.53 $ |
Dividend (TTM) |
0 $ |
|
|
|
|